当前位置: 首页 > 详情页

HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]China Med Univ, Hosp 1, Dept Neurosurg, Shenyang 110001, Peoples R China; [2]CGCG, Beijing, Peoples R China; [3]Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China; [4]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China; [5]Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin, Peoples R China; [6]Dalian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Dalian, Peoples R China; [7]China Med Univ, Hosp 1, Dept Neurosurg, Nanjing St 155, Shenyang 110001, Peoples R China
出处:
ISSN:

关键词: Glioma HDAC4 Chromosomal instability MGMT promoter methylation Prognosis

摘要:
Chromosomal instability is a hallmark of human cancers and is closely linked to tumorigenesis. The prognostic value of molecular signatures of chromosomal instability (CIN) has been validated in various cancers. However, few studies have examined the relationship between CIN and glioma. Histone deacetylases (HDACs) regulate chromosome structure and are linked to the loss of genomic integrity in cancer cells. In this study, the prognostic value of HDAC4 expression and its association with markers of CIN were investigated by analyzing data from our own and four other large sample databases. The results showed that HDAC4 expression is downregulated in high- as compared to low-grade glioma and is associated with a favorable clinical outcome. HDAC4 expression and CIN were closely related in glioma from both functional and statistical standpoints. Moreover, the predictive value of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status-a widely used glioma marker-was refined by HDAC4 expression level, which was significantly related to CIN in our study. In conclusion, we propose that HDAC4 expression, a prognostic and CIN marker, enhances the predictive value of MGMT promoter methylation status for identifying patients who will most benefit from radiochemotherapy.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 3 区 医学
小类 | 3 区 临床神经病学 3 区 肿瘤学
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 临床神经病学 3 区 肿瘤学
JCR分区:
出版当年[2013]版:
Q2 ONCOLOGY Q2 CLINICAL NEUROLOGY
最新[2023]版:
Q2 CLINICAL NEUROLOGY Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]China Med Univ, Hosp 1, Dept Neurosurg, Shenyang 110001, Peoples R China; [2]CGCG, Beijing, Peoples R China;
通讯作者:
通讯机构: [1]China Med Univ, Hosp 1, Dept Neurosurg, Shenyang 110001, Peoples R China; [2]CGCG, Beijing, Peoples R China; [7]China Med Univ, Hosp 1, Dept Neurosurg, Nanjing St 155, Shenyang 110001, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院